These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 21888570)
1. Abobotulinum toxin A and onabotulinum toxin A for masseteric hypertrophy: a split-face study in 25 Korean patients. Lee SH; Wee SH; Kim HJ; Yeo UC; Lee NH; Lee SW; Cho SB J Dermatolog Treat; 2013 Apr; 24(2):133-6. PubMed ID: 21888570 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of incobotulinum toxin A in periocular rhytides and masseteric hypertrophy: side-by-side comparison with onabotulinum toxin A. Lee JH; Park JH; Lee SK; Han KH; Kim SD; Yoon CS; Park JY; Lee JH; Yang JM; Lee JH J Dermatolog Treat; 2014 Aug; 25(4):326-30. PubMed ID: 23356833 [TBL] [Abstract][Full Text] [Related]
3. Lower facial remodeling with botulinum toxin type A for the treatment of masseter hypertrophy. Klein FH; Brenner FM; Sato MS; Robert FM; Helmer KA An Bras Dermatol; 2014; 89(6):878-84. PubMed ID: 25387491 [TBL] [Abstract][Full Text] [Related]
7. Intradetrusor injections of onabotulinum toxin A (Botox®) 300 U or 200 U versus abobotulinum toxin A (Dysport®) 750 U in the management of neurogenic detrusor overactivity: A case control study. Peyronnet B; Castel-Lacanal E; Roumiguie M; Even L; Marque P; Soulié M; Rischmann P; Game X Neurourol Urodyn; 2017 Mar; 36(3):734-739. PubMed ID: 27037973 [TBL] [Abstract][Full Text] [Related]
8. The change of maximum bite force after botulinum toxin type a injection for treating masseteric hypertrophy. Ahn KY; Kim ST Plast Reconstr Surg; 2007 Nov; 120(6):1662-1666. PubMed ID: 18040203 [TBL] [Abstract][Full Text] [Related]
9. Exploring botulinum toxin's impact on masseter hypertrophy: a randomized, triple-blinded clinical trial. de Souza Nobre BB; Rezende L; Barbosa Câmara-Souza M; Sanchez-Ayala A; Blass R; Carbone AC; Manso AC; Ernberg M; Christidis N; De la Torre Canales G Sci Rep; 2024 Jun; 14(1):14522. PubMed ID: 38914688 [TBL] [Abstract][Full Text] [Related]
10. Use of botulinum toxin type A for the treatment of masseteric muscle hypertrophy. Arikan OK; Tan FU; Kendi T; Koc C J Otolaryngol; 2006 Feb; 35(1):40-3. PubMed ID: 16527016 [TBL] [Abstract][Full Text] [Related]
11. Classification of masseter hypertrophy for tailored botulinum toxin type A treatment. Xie Y; Zhou J; Li H; Cheng C; Herrler T; Li Q Plast Reconstr Surg; 2014 Aug; 134(2):209e-218e. PubMed ID: 25068343 [TBL] [Abstract][Full Text] [Related]
12. Nonsurgical reshaping of the lower face. Liew S; Dart A Aesthet Surg J; 2008; 28(3):251-7. PubMed ID: 19083534 [TBL] [Abstract][Full Text] [Related]
13. Effects of botulinum toxin type A on bilateral masseteric hypertrophy evaluated with computed tomographic measurement. Kim HJ; Yum KW; Lee SS; Heo MS; Seo K Dermatol Surg; 2003 May; 29(5):484-9. PubMed ID: 12752515 [TBL] [Abstract][Full Text] [Related]
14. A Multicenter Phase II Study Evaluating the Safety and Efficacy of Botulax in Asian Patients with Benign Masseteric Hypertrophy. Lee JS; Son HS; Kim BJ; Lee YW Plast Reconstr Surg; 2024 May; 153(5):910e-918e. PubMed ID: 37335589 [TBL] [Abstract][Full Text] [Related]
15. Effects of botulinum toxin type A on contouring of the lower face. Choe SW; Cho WI; Lee CK; Seo SJ Dermatol Surg; 2005 May; 31(5):502-7; discussion 507-8. PubMed ID: 15962731 [TBL] [Abstract][Full Text] [Related]
16. The use of botulinum toxin type A in aesthetic mandibular contouring. Kim NH; Chung JH; Park RH; Park JB Plast Reconstr Surg; 2005 Mar; 115(3):919-30. PubMed ID: 15731696 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of a Novel Botulinum Toxin A for Masseter Reduction: A Randomized, Double-Blind, Placebo-Controlled, Optimal Dose-Finding Study. Hong JY; Jeong GJ; Kwon TR; Kim JH; Li K; Kim BJ Dermatol Surg; 2021 Jan; 47(1):e5-e9. PubMed ID: 33347002 [TBL] [Abstract][Full Text] [Related]
18. Dose conversion ratio, comparative efficacy, and adverse events after switching from onabotulinum toxin A to abobotulinum toxin A for neurological conditions. Ozer IS; Kuzu Kumcu M; Tezcan Aydemir S; Akbostanci MC Clin Neurol Neurosurg; 2021 Oct; 209():106889. PubMed ID: 34461363 [TBL] [Abstract][Full Text] [Related]
19. Paradoxical masseteric bulging after botulinum neurotoxin type A injection. Sandhu S; Shaefer J BMJ Case Rep; 2024 May; 17(5):. PubMed ID: 38749514 [TBL] [Abstract][Full Text] [Related]
20. A prospective study of the effect of botulinum toxin A on masseteric muscle hypertrophy with ultrasonographic and electromyographic measurement. To EW; Ahuja AT; Ho WS; King WW; Wong WK; Pang PC; Hui AC Br J Plast Surg; 2001 Apr; 54(3):197-200. PubMed ID: 11254408 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]